Blast transformation in chronic myelomonocytic leukemia

Risk factors, genetic features, survival, and treatment outcome

Mrinal M Patnaik, Emnet A. Wassie, Terra L. Lasho, Curtis A. Hanson, Rhett Ketterling, Ayalew Tefferi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Among 274 patients with chronic myelomonocytic leukemia (CMML) and followed for a median of 17.1 months, blast transformation (BT) occurred in 36 (13%). On multivariable analysis, risk factors for BT were presence of circulating blasts (HR 5.7; 95% CI 2.8-11.9) and female gender (HR 2.6; 95% CI 1.3-5.1); the results remained unchanged when analysis was restricted to CMML-1. ASXL1/SRSF2/SF3B1/U2AF1/SETBP1 mutational frequencies were not significantly different between time of CMML diagnosis and BT. Median survival post-BT was 4.7 months (5-year survival 6%) and better with allogeneic stem cell transplant (SCT) (14.3 months vs. 4.3 months for chemotherapy vs. 0.9 months for supportive care; P=0.03). Neither karyotype nor mutational status was independently associated with risk of BT or post-BT survival. We conclude that female patients with CMML and those with circulating blasts are at a higher risk of BT. Post-BT survival is dismal and our observations suggest consideration of allogeneic SCT prior to BT.

Original languageEnglish (US)
Pages (from-to)411-416
Number of pages6
JournalAmerican Journal of Hematology
Volume90
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Leukemia, Myelomonocytic, Chronic
Lymphocyte Activation
Survival
Stem Cells
Transplants
Karyotype
Drug Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Blast transformation in chronic myelomonocytic leukemia : Risk factors, genetic features, survival, and treatment outcome. / Patnaik, Mrinal M; Wassie, Emnet A.; Lasho, Terra L.; Hanson, Curtis A.; Ketterling, Rhett; Tefferi, Ayalew.

In: American Journal of Hematology, Vol. 90, No. 5, 01.05.2015, p. 411-416.

Research output: Contribution to journalArticle

Patnaik, Mrinal M ; Wassie, Emnet A. ; Lasho, Terra L. ; Hanson, Curtis A. ; Ketterling, Rhett ; Tefferi, Ayalew. / Blast transformation in chronic myelomonocytic leukemia : Risk factors, genetic features, survival, and treatment outcome. In: American Journal of Hematology. 2015 ; Vol. 90, No. 5. pp. 411-416.
@article{4c64b3d2a37e45c48ff538d776ec7084,
title = "Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome",
abstract = "Among 274 patients with chronic myelomonocytic leukemia (CMML) and followed for a median of 17.1 months, blast transformation (BT) occurred in 36 (13{\%}). On multivariable analysis, risk factors for BT were presence of circulating blasts (HR 5.7; 95{\%} CI 2.8-11.9) and female gender (HR 2.6; 95{\%} CI 1.3-5.1); the results remained unchanged when analysis was restricted to CMML-1. ASXL1/SRSF2/SF3B1/U2AF1/SETBP1 mutational frequencies were not significantly different between time of CMML diagnosis and BT. Median survival post-BT was 4.7 months (5-year survival 6{\%}) and better with allogeneic stem cell transplant (SCT) (14.3 months vs. 4.3 months for chemotherapy vs. 0.9 months for supportive care; P=0.03). Neither karyotype nor mutational status was independently associated with risk of BT or post-BT survival. We conclude that female patients with CMML and those with circulating blasts are at a higher risk of BT. Post-BT survival is dismal and our observations suggest consideration of allogeneic SCT prior to BT.",
author = "Patnaik, {Mrinal M} and Wassie, {Emnet A.} and Lasho, {Terra L.} and Hanson, {Curtis A.} and Rhett Ketterling and Ayalew Tefferi",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/ajh.23962",
language = "English (US)",
volume = "90",
pages = "411--416",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Blast transformation in chronic myelomonocytic leukemia

T2 - Risk factors, genetic features, survival, and treatment outcome

AU - Patnaik, Mrinal M

AU - Wassie, Emnet A.

AU - Lasho, Terra L.

AU - Hanson, Curtis A.

AU - Ketterling, Rhett

AU - Tefferi, Ayalew

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Among 274 patients with chronic myelomonocytic leukemia (CMML) and followed for a median of 17.1 months, blast transformation (BT) occurred in 36 (13%). On multivariable analysis, risk factors for BT were presence of circulating blasts (HR 5.7; 95% CI 2.8-11.9) and female gender (HR 2.6; 95% CI 1.3-5.1); the results remained unchanged when analysis was restricted to CMML-1. ASXL1/SRSF2/SF3B1/U2AF1/SETBP1 mutational frequencies were not significantly different between time of CMML diagnosis and BT. Median survival post-BT was 4.7 months (5-year survival 6%) and better with allogeneic stem cell transplant (SCT) (14.3 months vs. 4.3 months for chemotherapy vs. 0.9 months for supportive care; P=0.03). Neither karyotype nor mutational status was independently associated with risk of BT or post-BT survival. We conclude that female patients with CMML and those with circulating blasts are at a higher risk of BT. Post-BT survival is dismal and our observations suggest consideration of allogeneic SCT prior to BT.

AB - Among 274 patients with chronic myelomonocytic leukemia (CMML) and followed for a median of 17.1 months, blast transformation (BT) occurred in 36 (13%). On multivariable analysis, risk factors for BT were presence of circulating blasts (HR 5.7; 95% CI 2.8-11.9) and female gender (HR 2.6; 95% CI 1.3-5.1); the results remained unchanged when analysis was restricted to CMML-1. ASXL1/SRSF2/SF3B1/U2AF1/SETBP1 mutational frequencies were not significantly different between time of CMML diagnosis and BT. Median survival post-BT was 4.7 months (5-year survival 6%) and better with allogeneic stem cell transplant (SCT) (14.3 months vs. 4.3 months for chemotherapy vs. 0.9 months for supportive care; P=0.03). Neither karyotype nor mutational status was independently associated with risk of BT or post-BT survival. We conclude that female patients with CMML and those with circulating blasts are at a higher risk of BT. Post-BT survival is dismal and our observations suggest consideration of allogeneic SCT prior to BT.

UR - http://www.scopus.com/inward/record.url?scp=84928301522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928301522&partnerID=8YFLogxK

U2 - 10.1002/ajh.23962

DO - 10.1002/ajh.23962

M3 - Article

VL - 90

SP - 411

EP - 416

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 5

ER -